Concerned about a lack of new and domestically developed drugs, the government of Korea is taking active steps to support and encourage the use of artificial intelligence (AI) in drug development. Read More
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients. Read More
A tissue-engineered knee meniscus, seeded with mesenchymal stem cells (MSCs) under biomechanical and biochemical stimuli in vitro, has been shown to promote anisotropy and have a functional chondroprotective effect on the knee, a Chinese study reported in the April 10, 2019, issue of Science Translational Medicine. Read More
KARACHI, Pakistan – Issues surrounding drug pricing and government policies are challenges for not only Pakistan's domestic pharmaceutical companies, but also multinational corporations, providing further evidence the current pricing debate is not just a Western problem. Read More
Noxopharm Ltd., of Sydney, reported preclinical results that Veyonda (idronoxil) activates cells associated with both the innate and adaptive immune systems, which increased the number of functional natural killer cells and CD4+ T-helper cells. The company is already testing Veyonda in combination with external beam radiotherapy and intravenous radiopharmaceuticals, but is now considering testing the drug with a checkpoint inhibitor. Read More
Now that hepatitis C virus has many therapeutic options, biopharma companies have turned their attention to finding a potential cure – or at least a functional cure – for hepatitis B virus (HBV), targeting not only the reservoir virus but also finding ways to boost immunity, as they continually seek research funding. Read More
Although the number of biopharma licensing deals signed in 2018 reached 1,364 with a projected value of $119.5 billion, a four-year high, it appears that number has not satisfied the industry's appetite for dealmaking just yet. According to data from BioWorld and Cortellis Deals Intelligence, there were 418 deals signed in the first quarter of 2019, a whopping 48% higher than the first quarter transactions completed last year. Read More
